TriangleNCT00520936 · OUTCOME
Percentage of Participants With Overall Tumor Response (Response Rate)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- Percentage of Participants
- Interval / dispersion
- Not reported
- Time frame
- baseline to measured progressive disease (up to 1 year)
What was measured
Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response = disappearance of all target lesions. Partial Response = 30% decrease in sum of longest diameter of target lesions. Response rate (percent \[%\])= (number of participants with complete response (CR) or partial response (PR) in stratum/number of participants in stratum)\*100.
Analysis population: All treated participants.
Groups in this outcome
Osteosarcoma
Pemetrexed 1910 milligrams per meters squared (mg/m\^2) (or 60 milligrams per kilogram \[mg/kg\] if patient \<12 months old)
Ewing's Sarcoma/Peripheral Primitive Neuroectodermal Tumors
Pemetrexed 1910 mg/m\^2 (or 60 mg/kg if patient \<12 months old)
Rhabdomyosarcoma
Pemetrexed 1910 mg/m\^2 (or 60 mg/kg if patient \<12 months old)
Neuroblastoma (Measureable Disease)
Pemetrexed 1910 mg/m\^2 (or 60 mg/kg if patient \<12 months old)
Neuroblastoma (Metaiodobenzylguanidine Positive Evaluable)
Pemetrexed 1910 mg/m\^2 (or 60 mg/kg if patient \<12 months old)
Ependymoma
Pemetrexed 1910 mg/m\^2 (or 60 mg/kg if patient \<12 months old)
Medulloblastoma/Supratentorial Primitive Neuroectodermal Tumor
Pemetrexed 1910 mg/m\^2 (or 60 mg/kg if patient \<12 months old)
Non-Brainstem High-Grade Glioma
Pemetrexed 1910 mg/m\^2 (or 60 mg/kg if patient \<12 months old)
| Group | Source count |
|---|---|
| Osteosarcoma | 10 |
| Ewing's Sarcoma/Peripheral Primitive Neuroectodermal Tumors | 11 |
| Rhabdomyosarcoma | 9 |
| Neuroblastoma (Measureable Disease) | 5 |
| Neuroblastoma (Metaiodobenzylguanidine Positive Evaluable) | 6 |
| Ependymoma | 10 |
| Medulloblastoma/Supratentorial Primitive Neuroectodermal Tumor | 11 |
| Non-Brainstem High-Grade Glioma | 10 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Osteosarcoma | 0 | Not reported | Not reported | Not reported | Not reported |
| Ewing's Sarcoma/Peripheral Primitive Neuroectodermal Tumors | 0 | Not reported | Not reported | Not reported | Not reported |
| Rhabdomyosarcoma | 0 | Not reported | Not reported | Not reported | Not reported |
| Neuroblastoma (Measureable Disease) | 0 | Not reported | Not reported | Not reported | Not reported |
| Neuroblastoma (Metaiodobenzylguanidine Positive Evaluable) | 0 | Not reported | Not reported | Not reported | Not reported |
| Ependymoma | 0 | Not reported | Not reported | Not reported | Not reported |
| Medulloblastoma/Supratentorial Primitive Neuroectodermal Tumor | 0 | Not reported | Not reported | Not reported | Not reported |
| Non-Brainstem High-Grade Glioma | 0 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 0
- group Id
- OG006
- value
- 0
- group Id
- OG007
- value
- 0
- denoms
- counts
- group Id
- OG000
- value
- 10
- group Id
- OG001
- value
- 11
- group Id
- OG002
- value
- 9
- group Id
- OG003
- value
- 5
- group Id
- OG004
- value
- 6
- group Id
- OG005
- value
- 10
- group Id
- OG006
- value
- 11
- group Id
- OG007
- value
- 10
- units
- Participants
- description
- Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response = disappearance of all target lesions. Partial Response = 30% decrease in sum of longest diameter of target lesions. Response rate (percent \[%\])= (number of participants with complete response (CR) or partial response (PR) in stratum/number of participants in stratum)\*100.
- groups
- description
- Pemetrexed 1910 milligrams per meters squared (mg/m\^2) (or 60 milligrams per kilogram \[mg/kg\] if patient \<12 months old)
- id
- OG000
- title
- Osteosarcoma
- description
- Pemetrexed 1910 mg/m\^2 (or 60 mg/kg if patient \<12 months old)
- id
- OG001
- title
- Ewing's Sarcoma/Peripheral Primitive Neuroectodermal Tumors
- description
- Pemetrexed 1910 mg/m\^2 (or 60 mg/kg if patient \<12 months old)
- id
- OG002
- title
- Rhabdomyosarcoma
- description
- Pemetrexed 1910 mg/m\^2 (or 60 mg/kg if patient \<12 months old)
- id
- OG003
- title
- Neuroblastoma (Measureable Disease)
- description
- Pemetrexed 1910 mg/m\^2 (or 60 mg/kg if patient \<12 months old)
- id
- OG004
- title
- Neuroblastoma (Metaiodobenzylguanidine Positive Evaluable)
- description
- Pemetrexed 1910 mg/m\^2 (or 60 mg/kg if patient \<12 months old)
- id
- OG005
- title
- Ependymoma
- description
- Pemetrexed 1910 mg/m\^2 (or 60 mg/kg if patient \<12 months old)
- id
- OG006
- title
- Medulloblastoma/Supratentorial Primitive Neuroectodermal Tumor
- description
- Pemetrexed 1910 mg/m\^2 (or 60 mg/kg if patient \<12 months old)
- id
- OG007
- title
- Non-Brainstem High-Grade Glioma
- param Type
- NUMBER
- population Description
- All treated participants.
- reporting Status
- POSTED
- time Frame
- baseline to measured progressive disease (up to 1 year)
- title
- Percentage of Participants With Overall Tumor Response (Response Rate)
- type
- PRIMARY
- unit Of Measure
- Percentage of Participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice